Renal failure in patients with cirrhosis: Hepatorenal syndrome and renal support strategies

Current Opinion in Anaesthesiology

Volumn 23, Issue 2, 2010, Pages 139-144

  Meltzer, Joseph ^a,b   Brentjens, Tricia E ^a,b,c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c Department of Liver Transplant Anesthesiology ^*  (United States)

Author keywords

Ascites; Cirrhosis; Hepatorenal syndrome; Portal hypertension; Renal failure

Indexed keywords

ACETYLCYSTEINE; ALBUMIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIBIOTIC AGENT; BICARBONATE; CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; DOPAMINE; FENOLDOPAM; MIDODRINE; NORADRENALIN; OCTREOTIDE; ORNIPRESSIN; PENTOXIFYLLINE; PLACEBO; PLASMA SUBSTITUTE; PROSTAGLANDIN; SOMATOSTATIN DERIVATIVE; STEROID; TERLIPRESSIN; VASOCONSTRICTOR AGENT; VASOPRESSIN; VASOPRESSIN DERIVATIVE;

ACUTE KIDNEY FAILURE; ADRENAL INSUFFICIENCY; ADULT RESPIRATORY DISTRESS SYNDROME; ALBUMIN DIALYSIS; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; BACTERIAL PERITONITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS HEMODIALYSIS; CRYSTALLOID; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FLUID RESUSCITATION; GASTROINTESTINAL HEMORRHAGE; HEMODIALYSIS; HEPATORENAL SYNDROME; HUMAN; INTENSIVE CARE UNIT; KIDNEY BLOOD FLOW; KIDNEY INJURY; KIDNEY PERFUSION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MONOTHERAPY; MORTALITY; PERITONEAL DIALYSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RENAL REPLACEMENT THERAPY; REVIEW; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

HEPATORENAL SYNDROME; HUMANS; KIDNEY FAILURE; KIDNEY FAILURE, ACUTE; LIVER CIRRHOSIS; RENAL REPLACEMENT THERAPY;

EID: 77952212214     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32833724a8     Document Type: Review

References (57)

1. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure: definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8: R204-R212.
2. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-231.
3. Gines P, Schrier RW. Renal failure and cirrhosis. N Engl J Med 2009; •• 361:1279-1290. This paper is an outstanding review of the topic of acute renal failure in patients with cirrhosis.
4. Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002;35:1179-1185. (Pubitemid 34454015)
5. Gonwa TA, Klintman GB, Levy M, et al. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995;59:361-365.
6. Kamath PS, Kim WR, and the Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology 2007;45:797-805.
7. Weismuller TJ, Prokein J, Becker T, et al. Prediction of survival after liver • transplant by pretransplant parameters. Scand J Gastroenterol 2008;43:736-746. A review of factors predictive of mortality in OLT
8. Mehta RL, Kellum JA, Shah SV, et al., and the Acute Kidney Injury Network. cute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
9. Cholongitas E, Calvaruso V, Senzolo M, et al. IFLE classification as predictive factor of mortality in patients with cirrhosis admitted to the intensive care unit. Gastroenterol Hepatol 2009;24:1639-1647.
10. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996;334:1448-1460.
11. Hecker R, Sherlock S. Electrolytes and circulatory changes in terminal liver failure. Lancet 1956;271:1121-1125.
12. Ruiz-del-Arbol L, Urman J, Fernandez J, et al. Systemic, renal and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210-1218.
13. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42:439-447.
14. Krag A, Bendtsen F, Moller S. Low cardiac output predicts development of • hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010;59:105-110. Online prepublication. These are some of the best data to support our growing understanding of the role of low cardiac output in the development of HRS.
15. Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis: a concensus workshop of the international ascites club. Gut 2007;56:1310-1318.
16. Arroyo V, Gines P, Gerbes A, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164-176.
17. Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome •• in patients with cirrhosis. J Hepatol 2008;48(Suppl 1): S93-S103. A review of the pathogenesis and current management of HRS.
18. Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005;41:1282-1289.
19. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003;362:1819-1827.
20. Houck PM, Bratzler DW, Bartlett JG, et al. Timing of antibiotic administration and outcomes for medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004;164:637-644.
21. Dellinger RP, Levy MM, Vincent JL, for the International Surviving Sepsis • Campaign Guidelines Committee. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327. Consensus guidelines for the management of severe sepsis
22. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-1377.
23. The NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-1297
24. The acute respiratory distress syndrome network: ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301-1308.
25. Tsai MH, Peng YS, Chen YC, et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology 2006;43:673-681.
26. Fernandez J, Escorsell A, Zabalza M, et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. Hepatology 2006;44:1288-1295.
27. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004;350:2247-2256. (Pubitemid 38669207)
28. Schortgen F, Lacherade JC, Bruneel F, et al. Effect of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomized study. Lancet 2001;357:911-916.
29. Brunkhorst FM, Engel C, Reinhart K, and German Competence Network Sepsis. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-139.
30. Krag A, Moller S, Bendtsen F, et al. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 2007;46:1863-1971.
31. Kiser TH, MacLaren R, Fish DN. Treatment of hepatorenal syndrome. Phar- •• macotherapy 2009;29:1196-1211. This is a comprehensive review of the current state of treatment for hepatorenal syndrome.
32. Phua J, Lee KH. Liver support devices. Curr Opin Crit Care 2008;14:208-215.
33. Stadlbauer V, Davies NA, Sen S, Jalan R. Artificial liver support systems in the management of complications of cirrhosis. Semin Liver Dis 2008;28:96-109.
34. Gonwa TA, Morris CA, Klintman GB, et al. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome: experience in 300 patients. Transplantation 1991;51:428-430.
35. Arroyo V, Terra C, Gines P. New treatments of hepatorenal syndrome. Semin Liver Dis 2006;26:254-264.
36. Jeyarajah DR, Gonwa TA, Klintman GB, et al. Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant. Transplantation 1997;64:1760-1765.
37. Davis CL. Impact of pretransplant renal failure: when is listing for kidney-liver indicated? Liver Transpl 2005;11: S35-S44.
38. Turban S, Thuluvath PJ, Atta MG. Hepatorenal syndrome. World J Gastroenterol 2007;13:4046-4055.
39. Townsend DR, Bagshaw SM, Gobney R T N, et al. Intraoperative renal support during liver transplantation. Liver Transpl 2009;15:73-78.
40. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55-64.
41. Brensing KA, Textor J, Perz J, et al. Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in nontransplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000;47:288-295.
42. Kiser TH, Fish DN, Parikh CR. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant 2005;20:1813-1820.
43. Moreau R, Durand F, Poynard T, et al. Terlipressin inpatients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923-930.
44. Gluud LL, Kjaer MS, Christensen E. Terlipressin for hepatorenal syndrome. Chochrane Database Syst Rev 2006;4: CD005162.
45. Sanyal AJ, Boyer T, Garcia-Tsao G, and The Terlipressin Study Group. A •• randomized, prospective, double-blind, placebo-controlled study of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360-1368. A well controlled study of terlipressin in the treatment of HRS.
46. Martin-Llahi M, Pepin MN, Guevara M, and the TAHRS Investigators. Terli- •• pressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352-1359. A well controlled study of terlipressin in the treatment of HRS.
47. Esrailiam E, Pantageo ER, Kyulo NL, et al. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Soc 2007;52:742-748.
48. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 2003;37:233-243.
49. Sort P, Navasa M, Castells L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-409.
50. Fernandez J, Navasa M, Soriano G, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818-824.
51. Akriviadis E, Botla R, Shakil O, et al. Pentoxifylline improves short-term survival in severe alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-1648.
52. Stacul F, Adam A, Becker C, et al. CIN Consensus Working Panel. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol 2006;98:59-77.
53. Tepel M, van ger Gliet M, Zidek W, et al. Prevention of radiographic-contrast: agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-184.
54. Marenzi G, Assanelli E, Bartorelli AL, et al. N-acetylcysteine and contrastinduced nephropathy in primary angioplasty. N Engl J Med 2006;354:2773-2782.
55. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004;291:2328-2334.
56. Goldfarb S, McCullogh PA, McDermott SB. Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computer tomography radiology, and interventional cardiology. Mayo Clin Proc 2009;84:170-179.
57. McCullough PA. Multimodality prevention of contrast-induced acute kidney injury. Am J Kidney Dis 2008;51:169-172.